Monday, October 26, 2026

Treasury Yields Surge to 4.32-4.34%, Crushing High-PEG Tech Valuations

The 10-Year Treasury yield has climbed from 3.97% to 4.32-4.34%, triggering valuation compression across high-growth technology stocks. Lightspeed Commerce fell 5.58% and Autodesk dropped 3.45% on May 12 while the broader market rose. Stocks with elevated PEG ratios face the sharpest repricing as rate expectations reset.

LM Salvado
LM Salvado

May 13, 2026

Treasury Yields Surge to 4.32-4.34%, Crushing High-PEG Tech Valuations
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The 10-Year Treasury yield has risen from 3.97% to 4.32-4.34%1, forcing a broad repricing of growth equity valuations. The move is not marginal — it shifts the discount rate applied to future earnings across every sector.

High-PEG stocks bear the heaviest burden. When yields rise, the present value of distant cash flows falls sharply. Companies priced on earnings years out suffer the most. This is not theory — it showed up directly in May 12 trading.

Lightspeed Commerce (LSPD) dropped 5.58%1 on a day the broader market gained. Autodesk fell 3.45%1 in the same session. CI&T has underperformed the S&P 500 year-to-date1. None of these declines followed negative company-specific news — the pressure came from the rate environment.

The PEG ratio (price-to-earnings divided by growth rate) measures how much investors pay per unit of future growth. DKS carries a PEG of 3.21 and Booz Allen Hamilton (BAH) sits at 4.451 — both well above industry norms. At 3.97% yields, those multiples were defensible. At 4.34%, the math changes.

The 10-Year Constant Maturity Rate moved from 4.29 to 4.34%1, confirming the yield pressure is broad and sustained, not a single-day spike. Markets are recalibrating the risk-free rate assumption embedded in every discounted cash flow model.

The pattern divides markets cleanly. Value stocks with near-term earnings and low PEG ratios are relatively insulated. Growth stocks — especially in software and AI infrastructure — see their valuation cushion erode with each basis point move higher.

Investors holding high-PEG positions face a structural headwind until yields stabilize or reverse. A threshold around 4.3% appears to accelerate the divergence between rate-sensitive growth names and the broader index. That threshold has now been crossed.

Portfolio construction that ignores duration risk in equity positions — not just bond positions — is the central mistake of this rate environment.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com